DIA to Shine Light on Newly Released PCAST Report

Share Article

“Reinventing the R&D Business Model: Heeding the President’s PCAST Report on Innovation” to be hosted by the Tufts Center for the Study of Drug Development.

DIA log

A consummate group of moderators and panelists will participate in an executive session at DIA’s 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science. The session, to be held on June 25 in Boston, will be hosted by the Tufts Center for the Study of Drug Development (CSDD) and focus on a report released in January by the President’s Council of Advisors on Science and Technology (PCAST). Included in the panel will be Bernard Munos, founder of InnoThink Center for Research in Biomedical Innovation, who was recently noted in FierceBiotech as one of the 25 most influential people in biopharma, and Dalvir Gill, CEO of TransCelerate Biopharma Inc.

With the landscape for biopharmaceuticals rapidly changing, this senior-level session will examine how companies across the pharmaceutical sector are transforming their R&D business models to meet current and future market demands. Along with R&D, the panel will address preclinical, clinical, regulatory, operations, portfolio management and marketing issues—all aspects of business development.

Susan Cantrell, director of DIA North America, said, “We are truly honored to have this panel, whose members bring unparalleled experience, expertise and thought leadership. With the insight of these esteemed panelists, we are certain this interactive session will provide invaluable information that will help companies to move their businesses forward. Their views and discussion of the PCAST report come at an exciting time as the country seeks to lead the world in health care innovation.”

The moderators and panelists include:

Kenneth I. Kaitin, Ph.D.
Professor and Director, CSDD
Tufts University School of Medicine

Kenneth A. Getz, MBA
Director of Sponsored Research, Tufts CSDD; Chairman, Center for Information and Study on Clinical Research Participation
Tufts University
DIA Chairman, 2011

Bernard Munos, MBA
InnoThink Center for Research in Biomedical Innovation

Tomasz Sablinski, M.D.
Founder and CEO
Transparency Life Sciences

Robert J. Franco, Ph.D.
PricewaterhouseCoopers LLP

Andy Lee, M.D.
Senior Vice President, Global Clinical Operations

Dalvir Gill, Ph.D.
TransCelerate Biopharma Inc.

Visit http://www.diahome.org/DIA2013 to learn more about DIA’s 2013 49th Annual Meeting. To schedule an interview with one of the panelists or to request a press credential, please contact Eric Rosen at eric(dot)rosen(at)diahome(dot)org or at 215.290.9153.

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health-care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C. and Latin America. Visit our website at diahome.org and follow DIA at: LinkedIn,Twitter, YouTube, Facebook, Flickr and Pinterest.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eric Rosen
Email >
Visit website